GYKI 52466 (dihydrochloride) (Standard)

GYKI 52466 (dihydrochloride) (Standard) is the analytical standard of GYKI 52466 (dihydrochloride) . This product is intended for research and analytical applications. GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research[1][2].

Product Specifications

CAS Number

[2319722-40-0]

UNSPSC

12352005

Target

IGluR; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Neurological Disease

Smiles

NC1=CC=C(C2=NN=C(C)CC3=CC4=C(OCO4)C=C32)C=C1.[H]Cl.[H]Cl

Molecular Formula

C17H17Cl2N3O2

Molecular Weight

366.24

References & Citations

[1]S D Donevan, et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10 (1) :51-9.|[2]A G Chapman, et al. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 1991 Jul;9 (2) :92-6.